drugset / Trial / NCT03267576
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
RandomizedCrossoverDouble-blindTreatment
Summary
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient glycemic coefficient of variation (CV), expressed as a ratio percentage of standard deviation (SD) to mean glucose levels.
Timeline
- Start
- 2017-10-27
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANAGLIFLOZIN ANHYDROUS | Small molecule | 300 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
| Background | Metformin | Small molecule | 1500 mg | Oral |